top of page
Browse by category
Search
Early-life exposure to endocrine-disrupting chemicals results in a higher preference for sugary and fatty foods later
Exposure to endocrine-disrupting chemicals in early life, including during gestation and infancy, results in a higher preference for...
Anti-obesity medications can raise testosterone levels in men
Anti-obesity medications can significantly raise testosterone levels and improve health outcomes for men with obesity or type 2 diabetes,...
Five-year RefluxStop outcomes demonstrate favourable food passageway-related outcomes
RefluxStop surgery (developed by Implantica) results in a favourable profile of food passageway-related outcomes throughout the five-year...
Tirzepatide plus menopause hormone therapy aids weight loss
Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with overweight...
Consuming more protein may protect semaglutide patients taking from muscle loss
Women and older adults taking the anti-obesity drug semaglutide may be at higher risk for muscle loss, but higher protein intake may help...
Obesity-associated cancer deaths triple over past two decades in the US
Cancer deaths linked to obesity have tripled in the US over the past two decades, according to a study being presented at ENDO 2025, the...
Pouch revision plus raRYGB is a promising approach for recurrent weight gain
Pouch revision in combination with ring-augmented Roux-en-Y gastric bypass (raRYGB) – using a MiniMizer Ring - appears to be a promising...
Amylyx Pharmaceuticals presents new data on Avexitide for post-bariatric hypoglycemia
Amylyx Pharmaceuticals has represented analyses from the Phase 2 PREVENT and Phase 2b clinical trials of avexitide, an investigational,...
World’s first bariatric robotic telesurgery performed in India
SS Innovations International has announced the successful completion of the world’s first bariatric robotic telesurgery utilising the...
Rhythm’s Bivamelagon achieved statistically significant and clinically meaningful reductions in BMI in patients with hypothalamic obesity
Rhythm Pharmaceuticals’ bivamelagon (formerly LB54640), an investigational oral melanocortin-4 receptor (MC4R) agonist, achieved...
Browse by tag
bottom of page